logo
  Join        Login             Stock Quote

Ambit Biosciences Sets IPO Pricing Between $13 And $15 Per Share

 May 02, 2013 02:22 PM
 


(By Balachander) Ambit Biosciences Corp., a kinase drug development company, plans to sell roughly 4.64 million shares in an initial public offering (IPO) of common stock at between $13.00 and $15.00 apiece. 

The San Diego, California-based biopharmaceutical company, which intends to list on the NASDAQ under the symbol "AMBT.", withdrew its $86 million IPO in 2010.

Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) a validated target in the treatment of acute myeloid leukemia (AML). 

Quizartinib is currently in Phase 2b clinical development in patients with relapsed/refractory AML who express a genetic mutation in FLT3. 

[Related -Bank Stocks: The Misbegottenness of the Volcker Rule Truly Knows No Bounds]

The company has partnered with Astellas Pharma Inc. for the worldwide co-development and commercialization of quizartinib.

Ambit plans to use the net proceeds from the offering of about $57.6 million and the concurrent private placement to fund the continued clinical development of quizartinib, its other programs and for working capital and other general corporate purposes.

The company's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. (TEVA). 

For the year ended 2012, the company posted a net loss attributable to Ambit of $26.65 million.

[Related -Citigroup Inc (C) Q4 Earnings Preview: What To Watch?]

Citigroup (C) and Leerink Swann are the joint bookrunners of the offering.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageWinter is Coming! Here's My Favorite Seasonal Trade

Over the years, I've been successful trading weather patterns as they relate to commodities such as crude read on...

article imageHow To Avoid 5 Common Investing Mistakes

When it comes to successful investing, the field of behavioral finance has shown that sometimes the worst read on...

article imageSector Detector: Bulls Go Down Swinging, Refusing To Give Up Much Ground

Although the stock market displayed weakness last week as I suggested it would, bulls aren’t going down read on...

article imageThe Bumpy Road Ahead To Policy Normalization

When the dust clears from tomorrow’s Fed announcement, the crowd’s expecting that the slow but persistent read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.